Chronic Visceral ASMD: A Patient Guide

Chronic Visceral Acid Sphingomyelinase Deficiency (ASMD) is a rare, systemic genetic disorder that fundamentally changes how your body manages cellular waste ^[1]. It belongs to a group of conditions known as lysosomal storage disorders, where the “recycling centers” of your cells lack a vital enzyme called acid sphingomyelinase (ASM). Without enough of this enzyme, a fatty substance called sphingomyelin cannot be broken down and instead begins to accumulate within various tissues ^[2]. This process is caused by pathogenic variants in the SMPD1 gene, meaning an individual must inherit a changed gene from both parents to be affected ^[1].

While the broader category of ASMD exists as a clinical continuum, the Chronic Visceral form—historically known as Niemann-Pick Type B—is distinguished by its primary impact on the body’s internal organs rather than the central nervous system ^[3]. Over time, the buildup of fats causes the liver and spleen to enlarge and can lead to stiffness in the lungs, making breathing more difficult. It also disrupts the balance of fats in the blood and can lower the count of platelets, which are necessary for proper clotting ^[4]. Because these effects happen gradually and vary significantly from person to person, the disease requires a personalized approach to care that addresses the unique way it manifests in each individual ^[5].

Evolving Care and What Treatment Can Do

Modern management of ASMD has evolved from simply treating individual symptoms to addressing the enzyme deficiency itself through Enzyme Replacement Therapy (ERT) ^[6]. A man-made version of the missing enzyme, known as olipudase alfa, is now used to help the body break down stored sphingomyelin and reduce the size of enlarged organs for many patients ^[7].

What treatment can and cannot do:

• It targets non-CNS disease: ERT is indicated specifically for the non-central nervous system manifestations of ASMD.
• It is not a cure: ERT is a lifelong therapy that replaces the missing enzyme but does not fix the underlying genetic cause.
• Outcomes vary: While clinical trials show improvements in lung function and organ size, individual responses depend on the baseline level of organ damage, such as established liver scarring (fibrosis) ^[8].

Because the body needs time to safely process the sudden release of these stored fats, this treatment begins with a careful, gradual dose-escalation process overseen by specialists ^[7].

Living well with Chronic Visceral ASMD involves consistent, lifelong partnership with a multidisciplinary care team, which often includes a genetic counselor to help interpret test results and discuss family planning ^[3]. Because the condition is systemic, doctors specializing in genetics, liver health, lung function, and blood disorders must work together to monitor your health. Regular surveillance of organ volumes, lung capacity, and blood markers allows your team to stay ahead of potential complications and adjust treatments. While a diagnosis of ASMD is life-changing, the combination of advanced therapies and proactive monitoring can help stabilize and manage the condition to support your quality of life ^[9].